Will this drug be the first treatment for NASH?

There has been some success in a clinical trial but specialists flag safety issues
Clare Pain

Interim results from a clinical trial of obeticholic acid for non-alcoholic steatohepatitis (NASH) show it significantly reduces fibrosis and will probably confer clinical benefit, international researchers report.

The trial, known as REGENERATE, is the first phase-3 trial of a drug for NASH to show a positive effect, the authors say.